卡介苗-谷氨酰胺疫苗保护效果的现状

Vaccine Research Pub Date : 2019-06-10 DOI:10.29252/vacres.6.1.29

P. Méndez-Samperio

{"title":"卡介苗-谷氨酰胺疫苗保护效果的现状","authors":"P. Méndez-Samperio","doi":"10.29252/vacres.6.1.29","DOIUrl":null,"url":null,"abstract":"Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The current status of bacillus Calmette‐Guérin vaccine protective efficacy\",\"authors\":\"P. Méndez-Samperio\",\"doi\":\"10.29252/vacres.6.1.29\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.\",\"PeriodicalId\":52727,\"journal\":{\"name\":\"Vaccine Research\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29252/vacres.6.1.29\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29252/vacres.6.1.29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

卡介苗（BCG）对肺结核（TB）的保护作用较差。然而，BCG是唯一获得许可的针对人类结核病的疫苗。这篇综述讨论了结核病疫苗开发领域的主要研究进展，并将总结开发更安全、更有效的结核病疫苗的现状和主要挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The current status of bacillus Calmette‐Guérin vaccine protective efficacy

Bacillus Calmette‐Guérin (BCG) vaccine against pulmonary tuberculosis (TB) exhibits poor protective efficacy. However, BCG is the only licensed vaccine against human TB. This review discusses the main research progress in the field of TB vaccine development and will summarize the current status as well as the main challenges for the development of a safer and more efficient TB vaccine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vaccine Research

自引率

0.00%

发文量

审稿时长

15 weeks